CA14161Y2006
© Newsfile
07.03.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure
News Preview
Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart TissueData Presented at The American College of Cardiology's 72nd Annual Scientific Session Together with the World Congress of Cardiology Oakville, Ontario--(Newsfile Corp. - March 7, 2023) -...
Themefolio
Profiler
Peergroup
© Newsfile
17.01.2023
CRDL
LISTED
TSX
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis
News Preview
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. StudyOakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic thera...
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis
News Preview
The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit ParticipantsInitiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - December 12, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
14.11.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
News Preview
Oakville, Ontario--(Newsfile Corp. - November 14, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced that on November 14, 2022...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
07.11.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis
News Preview
Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6Data Presented at The American Heart Association Scientific Sessions 2022 Oakville, Ontario--(Newsfile Corp. - November 7, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases
News Preview
Discontinues LANCER Trial due to Lack of Eligible Patients for RecruitmentCash Runway Now Extends into 2026Oakville, Ontario--(Newsfile Corp. - October 25, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-i...
Themefolio
Profiler
Peergroup
© Newsfile
03.10.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
News Preview
Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflamm...
Themefolio
Profiler
Peergroup
© Newsfile
28.09.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
News Preview
Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases ("CVD"), announced today t...
Themefolio
Profiler
Peergroup
© Newsfile
03.08.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis
News Preview
Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patientsOakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an a...
Themefolio
Profiler
Peergroup
© Newsfile
29.06.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
News Preview
Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announ...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2022
CRDL
LISTED
TSX
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT
News Preview
Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is ple...
Themefolio
Profiler
Peergroup
© Newsfile
09.06.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
News Preview
Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular disease, is pleased to announce that it h...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
19.05.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors
News Preview
Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis
News Preview
Third IND authorization for CardiolRx™ in cardiovascular diseaseStudy to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indicationsOakville, Ontario--(Newsfile Corp. - May 17, 2022) - Cardiol Therapeutics Inc. (NASDA...
Themefolio
Profiler
Peergroup
© Newsfile
24.03.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Year-End 2021 Update on Operations
News Preview
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditisMade strategic appointments to...
Themefolio
Profiler
Peergroup
© Newsfile
22.03.2022
CRDL
LISTED
TSX
Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit
News Preview
Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that Cardiol's Chief Medical Off...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors
News Preview
Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce that its Board of...
Themefolio
Profiler
Peergroup
© Newsfile
01.03.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial
News Preview
LANCER Trial expanded to include up to 20 Additional Clinical Research CentersOakville, Ontario--(Newsfile Corp. - March 1, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatmen...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2022
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
News Preview
Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Rid...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Closing of US$50 Million Public Offering
News Preview
Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, announced today the closing of its previously announced public offering (the...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
News Preview
Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health...
Themefolio
Profiler
Peergroup
© Newsfile
18.10.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada
News Preview
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - October 18, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage bi...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2021
CRDL
LISTED
TSX
Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
News Preview
Oakville, Ontario--(Newsfile Corp. - September 16, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it will present at the 2021 Cantor Virtual...
Themefolio
Profiler
Peergroup
© Newsfile
10.09.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020
News Preview
Oakville, Ontario--(Newsfile Corp. - September 10, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces the acceleration of the expiry date of all outstandin...
Themefolio
Profiler
Peergroup
© Newsfile
07.09.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors
News Preview
Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Es...
Themefolio
Profiler
Peergroup
© Newsfile
24.08.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis
News Preview
Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2021
CRDL
LISTED
TSX
Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"
News Preview
Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has received final approval from The Nasdaq Capital Market...
Themefolio
Profiler
Peergroup
© Newsfile
07.07.2021
CRDL
LISTED
TSX
Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman
News Preview
Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that its Board of Directors has appointed...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
News Preview
Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announces results from its Annual General and Special Me...
Themefolio
Profiler
Peergroup
© Newsfile
28.06.2021
CRDL
LISTED
TSX
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
News Preview
Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the Company's virtual Annual...
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Closes $22 Million Bought Deal Offering
News Preview
Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the closing of its previously announced "bought deal" short f...
Themefolio
Profiler
Peergroup
© Newsfile
28.04.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
News Preview
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - April 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a cli...
Themefolio
Profiler
Peergroup
© Newsfile
12.04.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)
News Preview
Results expected to support the Company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - April 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developi...
Themefolio
Profiler
Peergroup
© Newsfile
01.04.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
News Preview
Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Managem...
Themefolio
Profiler
Peergroup
© Newsfile
30.03.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer
News Preview
Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that Dr. Andrew Hamer has joined the Com...
Themefolio
Profiler
Peergroup
© Newsfile
02.03.2021
CRDL
LISTED
TSX
Cardiol Therapeutics stellt Antrag auf Nasdaq-Uplisting und erzielt Erlöse von mehr als 10 Mio. USD aus der Ausübung von Optionsscheinen und Optionen
News Preview
Oakville, Ontario--(Newsfile Corp. - Dienstag, 2. März 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" oder das "Unternehmen"), ein Biotechnologieunternehmen im klinischen Stadium mit Fokus auf der Entwicklung innovativer entzündungshemmender Therapien zur Behandlung von Herz-Kreislauf-Erkrankungen gab heute...
Themefolio
Profiler
Peergroup
© Newsfile
02.03.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options
News Preview
Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has submitted an application to u...
Themefolio
Profiler
Peergroup
© Newsfile
21.01.2021
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
News Preview
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, Ontario--(Newsfile Corp. - January 21, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage bi...
Themefolio
Profiler
Peergroup
© Newsfile
07.01.2021
CRDL
LISTED
TSX
Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences
News Preview
Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the followin...
Themefolio
Profiler
Peergroup
© Newsfile
22.12.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx(TM)
News Preview
Study results are expected to support the Company's plans to file an IND application with the FDA for a Phase II clinical trial in acute myocarditisOakville, Ontario--(Newsfile Corp. - December 22, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
News Preview
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease now being initiated at clinical centers in the United StatesOakville, Ontario--(Newsfile Corp. - December 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OT...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2020
CRDL
LISTED
TSX
Cardiol Therapeutics' Cortalex(TM) CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.
News Preview
The first pharmaceutically produced THC-free* extra-strength cannabidiol (CBD)Oakville, Ontario--(Newsfile Corp. - October 20, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased t...
Themefolio
Profiler
Peergroup
© Newsfile
30.09.2020
CRDL
LISTED
TSX
FDA Approves Landmark COVID/Heart/CBD Clinical Trial -- SECFilings.com
News Preview
Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outcomes for COVID-19 patients. The US Food and Drug Adminis...
Themefolio
Profiler
Peergroup
© Newsfile
25.09.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial
News Preview
Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)Oakville, Ontario--(Newsfile Corp. - September 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or t...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2020
CRDL
LISTED
TSX
Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition -- SECFilings.com
News Preview
Redondo Beach, California--(Newsfile Corp. - September 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) initiation of a Phase 1 clinical study, intended to assess t...
Themefolio
Profiler
Peergroup
© Newsfile
15.09.2020
CRDL
LISTED
TSX
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
News Preview
Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, announces that Cardiol's President and CEO,...
Themefolio
Profiler
Peergroup
© Newsfile
26.08.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)
News Preview
Study Designed to Support Cardiol Therapeutics' Phase 2 International Trial in Acute MyocarditisOakville, Ontario--(Newsfile Corp. - August 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular disease...
Themefolio
Profiler
Peergroup
© Newsfile
05.08.2020
CRDL
LISTED
TSX
Orphan Drug Designation Is Proven Path for CBD -- SECFilings.com
News Preview
Redondo Beach, California--(Newsfile Corp. - August 5, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how the past success of the orphan drug designation informs Cardiol Therapeutics Inc.'s (TSX: CRDL) (OTCQX: CRTPF) eff...
Themefolio
Profiler
Peergroup
© Newsfile
15.07.2020
CRDL
LISTED
TSX
Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.com
News Preview
Redondo Beach, California--(Newsfile Corp. - July 15, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing the connection between heart disease, COVID-19, and inflammation. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF),...
Themefolio
Profiler
Peergroup
© Newsfile
29.06.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
News Preview
Oakville, Ontario--(Newsfile Corp. - June 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has appointed Steven Grasso as Business A...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2020
CRDL
LISTED
TSX
David Elsley Files Early Warning Report for Cardiol Therapeutics
News Preview
Oakville, Ontario--(Newsfile Corp. - June 25, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), today announced that David Elsley, President and CEO of Cardiol, has filed an early warning report (the "Report") in respect of his ownership of class A common shares of the Company (the "Shares") under the Comp...
Themefolio
Profiler
Peergroup
© Newsfile
04.06.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
News Preview
Oakville, Ontario--(Newsfile Corp. - June 4, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the closing of its previously announced "bought deal" short form pro...
Themefolio
Profiler
Peergroup
© Newsfile
02.06.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Reports 2020 AGM Results
News Preview
Oakville, Ontario--(Newsfile Corp. - June 2, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, announces results from its Annual General Meeting ("AGM") of shareholders h...
Themefolio
Profiler
Peergroup
© Newsfile
29.05.2020
CRDL
LISTED
TSX
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 1st at 4:30 p.m. EDT
News Preview
Oakville, Ontario--(Newsfile Corp. - May 29, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it will webcast the Company's virtual Annua...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering
News Preview
Oakville, Ontario--(Newsfile Corp. - May 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with a syn...
Themefolio
Profiler
Peergroup
© Newsfile
13.05.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
News Preview
Oakville, Ontario--(Newsfile Corp. - May 13, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has entered into an agreement with Canaccord...
Themefolio
Profiler
Peergroup
© Newsfile
06.05.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19
News Preview
Oakville, Ontario--(Newsfile Corp. - May 6, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce the filing of a new patent application covering the us...
Themefolio
Profiler
Peergroup
© Newsfile
14.04.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Study Demonstrating its Proprietary Nanotechnology Targets Fibrous Tissue in the Heart
News Preview
Results showed a greater than 100-fold increase in uptake of Cardiol's nanoparticles in heart failure hearts compared with control heartsOakville, Ontario--(Newsfile Corp. - April 14, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) a...
Themefolio
Profiler
Peergroup
© Newsfile
01.04.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure
News Preview
Data Accepted for Presentation at the American College of Cardiology Annual MeetingOakville, Ontario--(Newsfile Corp. - April 1, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for h...
Themefolio
Profiler
Peergroup
© Newsfile
26.03.2020
CRDL
LISTED
TSX
Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A
News Preview
Oakville, Ontario--(Newsfile Corp. - March 26, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, today filed its audited Year-end Financial Statements and Management's Dis...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
